This site provides INTERCEPT product information for Health Care Professionals in the United States.

Webinars and Podcasts

The PIPER Phase IV Study:
Assessing the Safety of Pathogen
Reduced Platelets in a Large Study of
Platelet Transfusion-Associated
Pulmonary Injury

Pathogen reduction (PR) has become the leading strategy to protect the US platelet supply against transfusion transmitted infection and transfusion-associated graft vs. host disease, with over 1.4 million platelet components treated with the INTERCEPT® Blood System per year.1 Dr. Allison Wheeler of the University of Washington School of Medicine will describe the largest Phase 4 prospective study of platelet transfusion-associated pulmonary injury to-date in which the pulmonary safety of over 10,000 conventional and PR platelet components transfused to hematology-oncology patients are evaluated. Outcomes including incidence of treatment emergent acute respiratory distress syndrome (TE-ARDS), adverse events, and blood component utilization will be discussed.

Allison P Wheeler, MD, MSCI
Scientific Director
Washington Center for Bleeding Disorders

1. Estimate for platelet units treated with the INTERCEPT Blood System is based on the number of kits sold per year and total apheresis collections (Free RJ et al. Transfusion. 2023;1–11).

MKT-EN 00823

 

Watch the Replay
Runtime: 18 min